China Medical University Hospital 中國醫藥大學附設醫院

A New Chapter in Smart Health Collaboration: Insights from Singapore Singapore has become a leading model for digital health transformation in Asia — advancing “Hospitals without Walls” through strong governance, AI integration, and community-based care. To accelerate the development of smart healthcare and AI applications, Chief Secretary Dr. Wei-Cheng Chen led a delegation from CMUH to Singapore. The team met with Representative Dr. Chen-Yen Tung at the Taipei Representative Office and visited National University Hospital (NUH), Changi General Hospital (CGH), and Sengkang General Hospital (SKH) to explore Singapore’s digital health strategies and best practices. 🤝 Building on NUHS’s earlier visit to Taiwan, both sides engaged in in-depth discussions on AI clinical applications, cross-hospital collaboration, and patient safety management, further strengthening the professional partnership between CMUH and Singapore’s leading medical institutions. CMUH remains committed to global excellence in smart healthcare — fostering international collaboration, learning from innovation worldwide, and shaping a patient-centered and sustainable future together. #CMUH #SmartHealthcare #InternationalCollaboration #HospitalsWithoutWalls #SingaporeHealthSystem

🌐 CMUH Passes HIMSS DIAM Stage 7 — Completing the Full HIMSS Certification Suite China Medical University Hospital (CMUH) has achieved HIMSS Digital Imaging Adoption Model (DIAM) Stage 7 certification, marking the completion of its full HIMSS global digital-health portfolio. This milestone underscores CMUH’s leadership in AI-driven precision medicine and smart-hospital transformation, enhancing diagnosis, treatment efficiency, and patient safety across cardiology, oncology, pathology, and other specialties. 🏥 A Decade of Digital Transformation Since 2016, CMUH has systematically pursued HIMSS global standards to build a blueprint for a world-class smart hospital. Over the years, the hospital has achieved a full suite of top-tier recognitions: • 2023｜INFRAM Stage 7 and EMRAM re-certification • 2023｜HIMSS Davies Award of Excellence • 2023｜Highest global score in Digital Health Indicator (DHI) • 2025｜AMAM Stage 7 • 2025｜DIAM Stage 7 Together, these milestones demonstrate CMUH’s continuous drive to integrate AI, analytics, and digital imaging into clinical practice — setting a benchmark for smart healthcare across Asia and beyond. #HIMSS #DIAMStage7 #SmartHospital #DigitalHealth #CMUH #HealthcareExcellence

🌍 CMUH & Shine-On Biomedical Partner with Nobel Laureate Dr. Randy Schekman to Drive Global EV Therapeutics Innovation We’re proud to announce a groundbreaking milestone in Taiwan’s biomedical journey! At the NextGen EV Therapeutics Forum, hosted by China Medical University and Healthcare System, we welcomed world-renowned scientists and innovators from Taiwan and the U.S. to spotlight the future of extracellular vesicle (EV) therapeutics.   🔬 Key Highlights: 🔹Strategic partnership with Shine-On Biomedical featuring Dr. Randy W. Schekman, 2013 Nobel Laureate, as International Scientific Advisor   🔹Launch of SOB100 – the world’s first exosome platform targeting HLA-G tumors, with FDA clearance for Phase I trials and publication in Nature Communications   🔹Keynote by Dr. Kenneth Witwer, President of ISEV, calling for global EV standardization   🔹Showcasing CMU’s innovations: dual-gene EVs, nanobody precision delivery, and GMP EV manufacturing   This collaboration marks a critical step toward a globally connected ecosystem for next-generation precision medicine—centered around the clinical potential of engineered EVs in cancer, neurodegenerative diseases, and immune modulation.   #EVTherapeutics #PrecisionMedicine #Exosomes #CMUH #ShineOnBiomedical #NobelLaureate

Pioneering a New Era in Cancer Therapy – World's First HLA-G Targeted Exosome Platform Enters U.S. Clinical Trials China Medical University Hospital, Taiwan, is proud to announce a groundbreaking advancement in cancer treatment: the world's first exosome-based drug delivery platform targeting HLA-G—SOB100—has officially received FDA clearance to begin Phase I clinical trials in the United States.   Developed under the leadership of Dr. Der-Yang Cho, Superintendent of CMUH, in collaboration with Shine-On Biomedical Co., SOB100 represents a groundbreaking advancement in precision oncology. Published in Nature Communications, this innovation leverages nanobody-engineered exosomes to selectively target HLA-G, an immune checkpoint molecule exploited by many aggressive tumors to evade detection.   💡 Breakthrough Features of SOB100: - First-in-class platform for targeted exosome therapy - Demonstrated ability to cross the blood-brain barrier and treat hard-to-reach tumors such as glioblastoma and triple-negative breast cancer - Designed to deliver both small molecules and nucleic acid drugs with high specificity and low toxicity As the first exosome platform globally to achieve this level of targeted precision, SOB100 is positioned to reshape how we approach cancer therapy—offering new hope for patients facing drug-resistant or advanced-stage cancers.   At CMUH, we are committed to pushing the boundaries of biomedical innovation and delivering cutting-edge therapies from the bench to the bedside—and now, to the global stage.   🌐 This achievement also highlights Taiwan's leadership in biotech innovation, opening new avenues for international collaboration and commercialization in next-generation cancer therapy.   #CMUH #ExosomeTherapy #PrecisionMedicine #CancerResearch #SOB100 #Biotech #FDAApproval #Glioblastoma #BreastCancer #DrugDelivery

Bridging Global Medical Innovation | A Visit from Mayo Clinic's Expert To strengthen global collaboration in healthcare innovation, we were honored to welcome Dr. Mohamad Adnan Alkhouli, Vice Chair of the Department of Cardiovascular Medicine at Mayo Clinic and a world-renowned lead in structural heart disease interventions.   Invited by Dr. Shih-Sheng Chang, Director of CMUH's AI Center, Dr. Alkhouli delivered a compelling keynote titled “CV Innovation and Precision Medicine: Will AI and Other Emerging Technologies Bridge the Gap?” His talk ignited rich discussions among our clinical leaders, exploring both the transformative promise and real-world challenges of integrating AI into cardiovascular care.   During his visit, Dr. Alkhouli toured our HiThings Tele-ICU, AI Center, and Proton Therapy Center, and met with President Mien-Chie Hung and Dr. Liang-Yo Yang at CMU's Shui-Nan Campus. He also engaged with our industry partner EVER FORTUNE.AI 長佳智能, expressing great interest in our ecosystem's efforts to combine AI with advanced medical treatments.   We sincerely thank Dr. Alkhouli for his insightful contributions and inspiring dialogue. We look forward to continuing and deepening our collaboration with Mayo Clinic to advanced smart healthcare globally. 中國醫藥大學附設醫院 人工智慧中心 EVER FORTUNE.AI 長佳智能 #MayoClinic #AIinMedicine #SmartHealthcare #ChinaMedicalUniversityHospital #CMUH

The CMU Museum of Fine Arts: A masterpiece of art and architecture that showcases Taiwan to the world Frank Gehry's only major project in East Asia   On May 3, the China Medical University & its Healthcare System marked a historic milestone—not in medicine, but in architecture and cultural vision.   We proudly marked the groundbreaking of the CMU Museum of Fine Arts, an inspiring new landmark designed by Pritzker Prize laureate Frank Gehry. This will be Gehry's only monumental creation in East Asia, and a cultural gift to Taiwan, crafted in shimmering stainless steel and cascading forms that interact poetically with light, sky, and city.   🌍 A Vision Beyond Medicine Guided by the vision of Chairman Chang-Hai Tsai, CMU & its Healthcare System are shaping a future where medicine, education, and the arts converge—and where Taiwan's voice resonates globally.   The CMU Museum of Fine Arts will stand as a beacon of that vision, forming global connections with institutions such as Harvard's Fogg Museum, Stanford's Cantor Arts Center, Oxford's Ashmolean Museum, and Cambridge's Fitzwilliam Museum.   This museum is more than an architectural landmark—it embodies a philosophy: That healing and inspiration are deeply interconnected. That great universities advance both scientific discovery and cultural dialogue.   And that Taiwan has a story to tell—one that deserves to be seen and celebrated by the world.   #CMUMFA #FrankGehry

🌍 Redefining the Future of Global Healthcare – From Taiwan to the World At China Medical University Hospital (CMUH), innovation is more than a mission—it’s a standard. As featured in Los Angeles Times, CMUH is transforming the global healthcare landscape through breakthroughs in: 🔬 Precision Medicine – Home to the world’s first FDA-approved clinical trial for allogeneic CAR-BiTE GDT therapy targeting solid tumors. 🤖 AI-Powered Healthcare – From real-time sepsis prediction to AI-assisted medical coding, our digital infrastructure helps physicians make faster, more accurate decisions. 🧬 Smart Exosomes – Engineered to deliver DNA, RNA, and proteins directly to target organs—enhancing therapeutic efficacy by up to 90 times. 🏆 Recognized with 17 Taiwan National Innovation Awards and 35 National Healthcare Quality Awards, CMUH is proud to be Taiwan’s most awarded hospital—and the only in the country to achieve HIMSS INFRAM 7, EMRAM 7, AMAM 7, and DIAM 6 certifications. As we continue to push the boundaries of biomedical science and smart medicine, we invite partners worldwide to join us in shaping the next era of healthcare. https://lnkd.in/gHWSEpcS #CMUH #SmartHealthcare #PrecisionMedicine #ExosomeInnovation #NewsweekBestHospitals

🏆 CMUH Wins Double Honors at the 2025 Healthcare Asia Awards: “Hospital of the Year” and “CEO of the Year” At the 2025 Healthcare Asia Awards, China Medical University Hospital (CMUH) was honored as “Hospital of the Year”, while Superintendent Dr. Der-Yang Cho received “CEO of the Year” — the only one healthcare leader in Asia-Pacific to be awarded this distinguished honor. These honors recognize our hospital's excellence in smart healthcare, biomedical innovation, and sustainable leadership across the region. From leading digital transformation to pioneering AI-powered medicine, cell therapy, and exosome research, CMUH continues to advance patient-first innovation through seven major interdisciplinary platforms. Notably, we developed the world's first FDA Phase I/IIa - approved allogeneic CAR.BiTE GDT cell therapy for solid tumors — a global breakthrough in cancer treatment. Our journey towards healthcare innovation and sustainability has been honored with several esteemed recognitions: ▪️ Newsweek's World's Best Hospitals & Smart Hospitals ▪️ HIMSS Certifications - Global highest score in DHI (Digital Healthcare Indicators) in 2023, INFRAM 7, EMRAM 7, AMAM 7, DIAM 6. ▪️Taiwan Sustainability Action Gold Award & the Asia-Pacific Sustainability Action Silver Award honored for significant contribution to sustainability As the sole recipient of “CEO of the Year” in the region, Superintendent Cho, an internationally acclaimed neurosurgeon and esteemed leader, reflected on this achievement: "One can go fast alone, but we can go far together. " This milestone is a testament to the collective dedication and hard work of the entire CMUH team—united by purpose, driven by compassion.We extend our heartfelt gratitude to our staff, patients, and the community for their unwavering support as we continue to strive for excellence in healthcare. " As we look ahead, CMUH remains committed to transforming healthcare for a smarter, healthier, and more sustainable future. #CMUH #SmartHealthcare #HealthcareLeadership #2025HealthcareAsiaAwards

CMUH: Taiwan's First Hospital to Achieve HIMSS AMAM Stage 7 Certification – Leading the Future of Smart Healthcare We're proud to announce that China Medical University Hospital (CMUH) has become Taiwan's first hospital to receive #HIMSS AMAM Stage 7 certification – representing the highest global standard in medical data analytics, underscoring CMUH's commitment to AI-driven precision medicine and smart healthcare innovation.   From ICU care and surgical recovery to medical records and hospital management, AI is transforming patient care at CMUH: 🔹 ICU mortality reduced by 5.4% 🔹 Hospital stays shortened by 23% 🔹 Documentation time cut by 85% 🔹 Inventory costs reduced by 20% 🔹 Carbon emissions lowered by 518 kg/year   Building on our previous achievements — HIMSS INFRAM Stage 7, EMRAM Stage 7, DHI (Global No.1), DIAM Stage 6, and the HIMSS Davies Award of Excellence — CMUH continues to lead the way in Smart Healthcare 4.0.   We're not just transforming systems. We're redefining the future of patient care.   Thank you to all CMUH colleagues for your dedication, and to HIMSS for continued support. Together, we're advancing the future of Smart Healthcare.   #HIMSS #SmartHealthcare #CMUH